PX1 Research provides analytical-grade Ipamorelin and CJC-1295 formulated strictly for laboratory evaluation in cell culture and animal models. Manufactured in USA-based, GMP-compliant facilities, every lot undergoes rigorous third-party verification via RP-HPLC, tandem Mass Spectrometry, and limulus amebocyte lysate endotoxin testing. Access pristine, fully traceable research compounds designed for high-reproducibility endocrinology studies.
PX1 Research provides analytical-grade Ipamorelin and CJC-1295 formulated strictly for laboratory evaluation in cell culture and animal models. Manufactured in USA-based, GMP-compliant facilities, every lot undergoes rigorous third-party verification via RP-HPLC, tandem Mass Spectrometry, and limulus amebocyte lysate endotoxin testing. Access pristine, fully traceable research compounds designed for high-reproducibility endocrinology studies.
Researchers sourcing high-purity ipamorelin and CJC-1295 research compounds require high-purity, analytical-grade peptides formulated strictly for laboratory research use. When combined in vitro or in animal models, this dual-peptide regimen synergistically stimulates somatotrophs via distinct GHRH and GHS-R1a receptor pathways, amplifying growth hormone secretion and downstream IGF-1 expression without elevating off-target hormones.
To ensure internal validity and cross-study reproducibility, laboratories must acquire reagents verified by objective analytical methods. Impurities, truncated peptide fragments, or residual TFA (trifluoroacetic acid) can alter receptor binding kinetics and skew experimental assay results. PX1 Research supplies high-purity, USA-manufactured peptides engineered to meet strict institutional parameters.
The co-administration of CJC-1295 and Ipamorelin represents a primary model for studying physiological growth hormone (GH) axis amplification. In pituitary cell cultures and rodent models, growth hormone release is regulated by two convergent signaling Cascades: Growth Hormone-Releasing Hormone (GHRH) receptor activation and Growth Hormone Secretagogue Receptor (GHS-R1a) stimulation.
CJC-1295 functions as a synthetic GHRH analog, binding to the GHRH receptor on anterior pituitary somatotrophs. This binding event triggers the G alpha s protein subunit, stimulating adenylate cyclase to increase intracellular cyclic AMP (cAMP) and activate protein kinase A (PKA). Concurrently, Ipamorelin acts as a selective ghrelin receptor agonist, targeting GHS-R1a. Activation of GHS-R1a initiates a G alpha q-mediated pathway, activating phospholipase C (PLC) and mobilizing intracellular calcium via inositol trisphosphate (IP3). Preclinical studies suggest that activating both the cAMP/PKA and PLC/Ca2+ signaling cascades simultaneously produces a supra-additive or synergistic release of GH compared to either compound tested in isolation.
Extensive in vitro assays and animal studies have characterized the secretory profiles generated by these two peptides. CJC-1295 was developed to preserve the natural biological activity of human GHRH while offering superior metabolic stability against enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). As a long-acting GHRH analog, CJC-1295 elevates baseline growth hormone secretion and sustains downstream insulin-like growth factor 1 (IGF-1) levels, which are critical parameters in tissue repair, cellular proliferation, and metabolic signaling research.
In contrast, the selective ghrelin receptor agonist ipamorelin induces discrete, high-amplitude GH pulses that mimic endogenous physiological spikes. In vivo rodent models demonstrate that combining a sustained GHRH signal with a targeted GHS-R pulse amplifies the total peak volume of growth hormone secreted over defined research intervals. This dual action facilitates targeted investigation into downstream anabolic markers, hepatic IGF-1 transcription, and cellular regeneration pathways without requiring continuous recombinant GH administration.
In chemical structure, CJC-1295 No DAC (also known as Modified GRF 1-29) is a 29-amino acid peptide incorporating specific amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that shield the N-terminal region from rapid DPP-IV degradation. This modification extends its biological half-life in laboratory assays from minutes to approximately 30 minutes, allowing adequate windowing for cellular signaling studies.
When synthesized with Drug Affinity Complex (DAC), the peptide covalently binds to circulating serum albumin via a maleimide linker, extending the elimination half-life significantly to several days in animal models. Researchers selecting between CJC-1295 with DAC and CJC-1295 No DAC base their selection on whether the experimental protocol calls for continuous baseline elevation or discrete, intermittent physiological signaling.
A critical feature of Ipamorelin highlighted across preclinical literature is its exceptional receptor selectivity. Earlier generations of growth hormone secretagogues, such as GHRP-6 and GHRP-2, bind to GHS-R1a but frequently induce off-target stimulation of the adrenocorticotropic hormone (ACTH) and prolactin pathways, leading to elevated cortisol and prolactin levels in animal models.
In vitro competitive binding studies and radioimmunoassays show that Ipamorelin binds exclusively to GHS-R1a with high affinity, failing to stimulate ACTH, cortisol, prolactin, or aldosterone release even at elevated concentrations. This clean selectivity profile renders Ipamorelin an ideal candidate for baseline growth hormone research, where secondary hormonal spikes would introduce confounding variables into tissue culture or metabolic assays.
Maintaining structural integrity during reconstitution and storage is essential for preserving peptide biological activity. Lyophilized Ipamorelin and CJC-1295 are shipped as stable powders under vacuum or inert gas flushing. Upon receipt, lyophilized vials should be stored in a dry, dark environment at -20°C for long-term preservation, or at 2–8°C for short-term bench top projects.
For laboratory reconstitution, researchers should utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile endotoxin-free water depending on the assay requirements. Reconstitution should involve gently directing the diluent down the glass vial wall rather than directly onto the lyophilized cake, followed by gentle swirling without vigorous agitation to prevent mechanical shear stress and peptide denaturation. Reconstituted solutions must be aliquot-frozen or stored at 2–8°C and evaluated within established stability windows.
When designing GH axis protocols, investigators frequently compare the Ipamorelin/CJC-1295 combination against alternative secretagogues available in the literature. Traditional hexapeptides like GHRP-6 and GHRP-2 provide potent GH release but exhibit notable ghrelin-mimicking side effects, such as dramatic appetite stimulation via hypothalamic NPY activation, alongside modest cortisol elevation. Conversely, baseline GHRH fragments like Sermorelin offer precise endogenous stimulation but possess extremely short half-lives due to rapid enzymatic clearing by DPP-IV.
The combination of CJC-1295 and Ipamorelin bypasses these limitations by merging enhanced enzymatic stability with absolute GHS-R1a selectivity. The resulting profile provides high secretagogue potency, sustained baseline elevation, and zero non-target pituitary hormone activation, making it the preferred standard for rigorous endocrine and cellular repair models. Investigators can explore our complete catalog of USA-manufactured peptides for alternative research candidates.
Acquiring reliable research results requires verified chemical purity. PX1 Research subjects every synthesized lot of CJC-1295 and Ipamorelin to strict analytical verification. Each shipment is backed by a lot-specific Certificate of Analysis (COA) generated by an independent, ISO 17025 accredited testing facility.
Analytical verification involves two primary methodologies: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). RP-HPLC quantifies chemical purity, ensuring that target peptide concentrations exceed 99% with minimal synthesis byproducts or residual organic solvents. ESI-MS verifies exact molecular mass against theoretical sequence weights, confirming sequence identity and the absence of truncated amino acid impurities.
For cell culture experiments and sensitive preclinical animal models, bacterial endotoxins pose a primary threat to experimental integrity. Endotoxins (lipopolysaccharides) induce non-specific inflammatory responses, cytokine cascades, and cellular toxicity that mask experimental readouts or invalidate animal model survival rates.
PX1 Research manufactures peptides in state-of-the-art, GMP-compliant facilities within the United States. Utilizing solid-phase peptide synthesis (SPPS) followed by rigorous purification and automated lyophilization under ISO 5 cleanroom standards, our compounds undergo Limulus Amebocyte Lysate (LAL) testing to guarantee endotoxin levels below 0.5 EU/mg. This level of purity ensures that observed cellular responses are directly attributable to peptide-receptor interaction rather than bacterial contamination.
PX1 Research operates dedicated fulfillment hubs in California and Arizona, providing rapid dispatch for time-sensitive research projects. Orders placed Monday through Friday ship same-day, arriving in temperature-controlled, protective packaging to shield sensitive peptide structures from environmental degradation during transit.
Whether securing single-vial batches for preliminary testing or accessing wholesale lab procurement services for institution-wide research, PX1 Research provides transparent batch tracking, verifiable documentation, and expert technical support. Explore detailed compound documentation in our PX1 Research scientific database or review our ghrp-2-vs-ipamorelin research analysis to refine your experimental design.
What is the primary objective of studying Ipamorelin and CJC-1295 together?
Researchers investigate Ipamorelin and CJC-1295 together to study dual-pathway somatotroph activation. CJC-1295 acts on the GHRH receptor, while Ipamorelin targets the GHS-R1a receptor. Preclinical studies suggest their combined action produces a synergistic release of growth hormone superior to either compound alone.
What is the purity standard for PX1 Research CJC-1295 and Ipamorelin?
All peptide lots sold by PX1 Research undergo RP-HPLC testing to ensure a chemical purity equal to or exceeding 99%. Identity is confirmed via Mass Spectrometry, and every lot includes an accessible ISO 17025 COA.
How should CJC-1295 and Ipamorelin be stored upon arrival?
Lyophilized vials should be stored at -20°C for long-term storage or 2–8°C for immediate laboratory use. Once reconstituted with sterile Bacteriostatic Water, solutions must be kept refrigerated at 2–8°C and shielded from direct light.
Are these compounds approved for human consumption or clinical administration?
No. Ipamorelin and CJC-1295 are supplied strictly as research chemical compounds for in vitro and preclinical laboratory evaluation. They are not intended for human or animal therapeutic, clinical, or diagnostic use.
What is the difference between CJC-1295 with DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a Drug Affinity Complex that covalently binds to plasma albumin, extending its plasma half-life to several days in animal models. CJC-1295 No DAC (Modified GRF 1-29) lacks this complex, yielding a half-life of approximately 30 minutes for shorter, pulsatile signaling studies.
How does PX1 Research limit endotoxins in peptide formulations?
Peptides are synthesized in USA-based, GMP-compliant facilities under sterile cleanroom conditions. Lots undergo LAL assay testing to confirm endotoxin levels remain below 0.5 EU/mg, minimizing off-target immune response in biological assays.
What diluent should be used for reconstituting peptide vials in a lab setting?
Laboratory protocols typically utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use analytical assays or sterile 0.9% sodium chloride / endotoxin-free water for sensitive biological testing, adhering to aseptic technique.
Where are PX1 Research peptides synthesized and shipped from?
PX1 Research peptides are synthesized in USA facilities and dispatched directly from our centralized fulfillment centers in California and Arizona with same-day shipping on business days.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.